Top Markets
Coin of the day
Rapid Therapeutic Science Laboratories, Inc. Rapid Therapeutic Science Laboratories, Inc.

Rapid Therapeutic Science Laboratories, Inc.

RTSL
Pozycja w akcjach #42555
Rapid Therapeutic Science Laboratories, Inc. (RTSL) is a biotechnology firm... Rapid Therapeutic Science Laboratories, Inc. (RTSL) is a biotechnology firm specializing in the aerosolized delivery of non-psychoactive cannabinoids directly into the bloodstream. This innovative approach is aimed at treating various conditions, including chronic pain, post-traumatic stress disorder (PTSD), insomnia, and aiding in surgery recovery, among other health issues. RTSL's product portfolio features pressurized meter dose inhalers (MDIs), designed to precisely dispense an aerosolized mist into the lungs, alongside sublingual oral spray devices. Furthermore, the company offers water-soluble cannabidiol (CBD) and cannabigerol (CBG) isolates under its "nhaler" brand. Established in 2013 and based in Dallas, Texas, the company adopted its current name, Rapid Therapeutic Science Laboratories, Inc., in January 2020, having previously operated as Holly Brothers Pictures, Inc. It was also formerly a subsidiary of Texas Mdi, Inc.
Cena akcji
$0.0001
Ostatnia synchronizacja: 2026-08-11
Kapitalizacja rynkowa
$883.00
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
-96.67%
Kraj
US
Handel Rapid Therapeutic Science Laboratories, Inc. (RTSL)

Kategoria

Zyski dla Rapid Therapeutic Science Laboratories, Inc. (RTSL)
Zyski w 2026 TTM: 0
Według najnowszych raportów finansowych Rapid Therapeutic Science Laboratories, Inc., obecny zysk firmy wynosi 0. W roku 2026 firma osiągnęła zysk w wysokości 0, równa się zysku z roku 2026, który wynosił 0. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Rapid Therapeutic Science Laboratories, Inc. od 2026 do 2026
Zyski na koniec każdego roku
Rok Zyski Zmień
Za mało danych dla podanych dat.
Zyski podobnych firm lub konkurentów
Firma Zyski Różnica w zyskach Kraj
$7.51B -
US
$5.15B -
US
$5.56B -
IE
$3.86B -
US
$1.42B -
US